SymBio Pharmaceuticals Limited
TSE Growth
¥57.00
-1.72%
Delayed · cached 15 min
Price Chart
Price50-day avg200-day avg
How to read this: the line is the closing price over time. The two dashed lines are moving averages — the average price over the last 50 and 200 trading days — which smooth out daily noise to show the broader trend. Price above its moving averages reflects recent strength; below reflects recent weakness. Use the buttons to change the time range. Prices are end-of-day, not live.
✓Strengths
- Current assets comfortably cover current liabilities (current ratio 2.96).
!Watch-points
- Higher leverage: debt-to-equity of 2.04 is above 1.
- Return on equity is on the lower side at -524.1%.
- Return on capital employed is on the lower side at -172.3%.
- The company reported a net loss in the latest period.
- Sales growth has been slow over five years (about -37% a year).
These points are generated automatically from the company’s reported figures to highlight what stands out. They are descriptive observations for educational purposes only — not advice or a recommendation to buy, sell, or hold.
Forensic Checks
Altman Z-ScoreDistress zone
-16.23
In Altman’s study, scores in this range were associated with a higher incidence of financial distress.
Computed without the market-value term.
Piotroski F-ScoreWeak
0 / 4
The F-Score adds one point for each of several year-on-year signs of improving profitability, lower leverage and better efficiency. Higher is generally stronger.
Based on 4 of the 9 signals — the rest need data not available for this stock.
These are well-known academic screening models, shown for educational context only. They describe historical financial patterns and are not predictions, advice, or a recommendation to buy, sell, or hold.
Key Ratios
Market Cap¥46億
Current Price¥ 57.00
High / Low¥ 229.00 / 55.00
Stock P/E-0.60
Book Value¥ 15.54
Dividend Yield0%
ROCE-172.32%
ROE-524.14%
Debt to Equity2.04
Current Ratio2.96
P/B Ratio-7.4636636
EPS¥ -95.12
PAT Margin-365.25%
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity